Characteristic | Groups | Actual value | Predicted value | Equated value | ||||||
---|---|---|---|---|---|---|---|---|---|---|
OLS5 | P | Tobit5 | P | TPM5 | P | OLS5 | P | |||
Health-care insurance | Urban employees | 0.871 | 0.870 | 0.002 | 0.866 | 0.003 | 0.869 | 0.002 | 0.872 | 0.002 |
Urban residents | 0.912 | 0.907 | 0.904 | 0.908 | 0.916 | |||||
New rural cooperative scheme | 0.825 | 0.826 | 0.822 | 0.827 | 0.820 | |||||
Other | 0.857 | 0.869 | 0.863 | 0.867 | 0.871 | |||||
Course of disease, month | ≤12 | 0.809 | 0.821 | <0.001 | 0.817 | 0.001 | 0.819 | <0.001 | 0.814 | <0.001 |
13~36 | 0.887 | 0.883 | 0.879 | 0.882 | 0.888 | |||||
37~60 | 0.912 | 0.896 | 0.893 | 0.895 | 0.904 | |||||
≥61 | 0.831 | 0.833 | 0.829 | 0.836 | 0.828 | |||||
TNM stage | 0 | 0.900 | 0.897 | 0.051 | 0.893 | 0.072 | 0.896 | 0.144 | 0.905 | 0.051 |
I | 0.899 | 0.892 | 0.888 | 0.890 | 0.899 | |||||
II | 0.869 | 0.864 | 0.860 | 0.863 | 0.866 | |||||
III | 0.844 | 0.835 | 0.831 | 0.835 | 0.831 | |||||
IV | 0.701 | 0.776 | 0.775 | 0.791 | 0.760 | |||||
Inpatient/Outpatient | Outpatient | 0.889 | 0.882 | <0.001 | 0.878 | <0.001 | 0.881 | <0.001 | 0.887 | <0.001 |
Inpatient | 0.685 | 0.723 | 0.720 | 0.726 | 0.696 | |||||
Endocrine therapy | No | 0.810 | 0.820 | 0.001 | 0.817 | 0.003 | 0.821 | 0.002 | 0.813 | 0.001 |
Yes | 0.878 | 0.873 | 0.869 | 0.873 | 0.877 | |||||
Disease state | Primary breast cancer within one year (state P) | 0.814 | 0.818 | <0.001 | 0.814 | <0.001 | 0.816 | <0.001 | 0.811 | <0.001 |
Primary and recurrent breast cancer for the second year and above (state S) | 0.904 | 0.893 | 0.888 | 0.892 | 0.900 | |||||
Recurrent breast cancer within one year (state R) | 0.779 | 0.776 | 0.773 | 0.782 | 0.760 | |||||
Metastatic cancer (state M) | 0.737 | 0.792 | 0.789 | 0.803 | 0.779 |